SPOP and posterior cortical atrophy: In vivo and in vitro experiments carried out revealed a novel BET and CBP inhibitor, NEO2734, is effective against the JQ1-resistant SPOP hotspot mutant, which could proceed further to clinical trials for effective anti-cancer therapy against SPOP-mutated PCa patients [43].